{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:20:53Z","timestamp":1791685253300,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302185"],"award-info":[{"award-number":["82302185"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005046","name":"Heilongjiang Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["PL2024H127"],"award-info":[{"award-number":["PL2024H127"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Postgraduate Research & Practice Innovation Program of Harbin Medical University","award":["YJSCX2024-56HYD"],"award-info":[{"award-number":["YJSCX2024-56HYD"]}]},{"name":"Key Project of Harbin Medical University Cancer Hospital Climbing Funding","award":["PDYS2024-03"],"award-info":[{"award-number":["PDYS2024-03"]}]},{"name":"Key Innovation Technology Project Harbin Medical University Cancer Hospital Innovation Technology Funding","award":["CXJSZD-2023-04"],"award-info":[{"award-number":["CXJSZD-2023-04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00259-025-07748-4","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:47:38Z","timestamp":1770079658000},"page":"3699-3710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CAIX-targeted PET\/CT in the evaluation of clear cell renal cell carcinoma: a head-to-head comparison with [18F]FDG PET\/CT"],"prefix":"10.1007","volume":"53","author":[{"given":"Wei","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudie","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7567-8663","authenticated-orcid":false,"given":"Dayong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2950-3288","authenticated-orcid":false,"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8776-5812","authenticated-orcid":false,"given":"Kezheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"7748_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"7748_CR2","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. https:\/\/doi.org\/10.1038\/nrdp.2017.9.","journal-title":"Nat Rev Dis Primers"},{"key":"7748_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","volume":"82","author":"H Moch","year":"2022","unstructured":"Moch H, Amin MB, Berney DM, Comperat EM, Gill AJ, Hartmann A, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2022;82:458\u201368. https:\/\/doi.org\/10.1016\/j.eururo.2022.06.016.","journal-title":"Eur Urol"},{"key":"7748_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","volume":"404","author":"M Young","year":"2024","unstructured":"Young M, Jackson-Spence F, Beltran L, Day E, Suarez C, Bex A, et al. Renal cell carcinoma. Lancet. 2024;404:476\u201391. https:\/\/doi.org\/10.1016\/S0140-6736(24)00917-6.","journal-title":"Lancet"},{"key":"7748_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","volume":"82","author":"L Bukavina","year":"2022","unstructured":"Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol. 2022;82:529\u201342. https:\/\/doi.org\/10.1016\/j.eururo.2022.08.019.","journal-title":"Eur Urol"},{"key":"7748_CR6","doi-asserted-by":"publisher","first-page":"42 e7","DOI":"10.1016\/j.urolonc.2019.10.004","volume":"38","author":"A Romeo","year":"2020","unstructured":"Romeo A, Garcia Marchinena P, Jurado AM, Gueglio G. Renal fossa recurrence after radical nephrectomy: current management, and oncological outcomes. Urol Oncol. 2020;38:42 e7-e12. https:\/\/doi.org\/10.1016\/j.urolonc.2019.10.004.","journal-title":"Urol Oncol"},{"key":"7748_CR7","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.2967\/jnumed.124.268509","volume":"65","author":"X Zhou","year":"2024","unstructured":"Zhou X, Wu Q, Zhai W, Zhang Y, Wu Y, Cao M, et al. CD70-Targeted Immuno-PET\/CT imaging of clear cell renal cell carcinoma: A translational study. J Nucl Med. 2024;65:1891\u20138. https:\/\/doi.org\/10.2967\/jnumed.124.268509.","journal-title":"J Nucl Med"},{"key":"7748_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01105-y","volume":"14","author":"FA Buttner","year":"2022","unstructured":"Buttner FA, Winter S, Stuhler V, Rausch S, Hennenlotter J, Fussel S, et al. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy. Genome Med. 2022;14:105. https:\/\/doi.org\/10.1186\/s13073-022-01105-y.","journal-title":"Genome Med"},{"key":"7748_CR9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2967\/jnumed.119.234278","volume":"61","author":"A Iravani","year":"2020","unstructured":"Iravani A, Hicks RJ. Imaging the cancer immune environment and its response to pharmacologic intervention, part 1: the role of (18)F-FDG PET\/CT. J Nucl Med. 2020;61:943\u201350. https:\/\/doi.org\/10.2967\/jnumed.119.234278.","journal-title":"J Nucl Med"},{"key":"7748_CR10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1007\/s00330-024-11094-8","volume":"35","author":"R Ebner","year":"2025","unstructured":"Ebner R, Sheikh GT, Brendel M, Ricke J, Cyran CC. ESR essentials: staging and restaging with FDG-PET\/CT in oncology-practice recommendations by the European society for hybrid, molecular and translational imaging. Eur Radiol. 2025;35:1894\u2013902. https:\/\/doi.org\/10.1007\/s00330-024-11094-8.","journal-title":"Eur Radiol"},{"key":"7748_CR11","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00259-020-04996-4","volume":"48","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Wu C, Li W, Chen X, Li Z, Liao X, et al. 2-[(18)F]FDG PET\/CT parameters associated with WHO\/ISUP grade in clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:570\u20139. https:\/\/doi.org\/10.1007\/s00259-020-04996-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7748_CR12","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1007\/s00259-021-05399-9","volume":"48","author":"C Wu","year":"2021","unstructured":"Wu C, Cui Y, Liu J, Ma L, Xiong Y, Gong Y, et al. Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[(18)F]FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48:4054\u201366. https:\/\/doi.org\/10.1007\/s00259-021-05399-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7748_CR13","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1007\/s11604-025-01761-1","volume":"43","author":"K Hirota","year":"2025","unstructured":"Hirota K, Ueno Y, Nogami M, Hyodo T, Tsuboyama T, Sofue K, et al. Role of (18)F-FDG-PET in renal tumors: insights from WHO 2022 classification. Jpn J Radiol. 2025;43:1078\u201389. https:\/\/doi.org\/10.1007\/s11604-025-01761-1.","journal-title":"Jpn J Radiol"},{"key":"7748_CR14","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Albiges L, Bex A, Comperat E, Grunwald V, Kanesvaran R, et al. Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:692\u2013706. https:\/\/doi.org\/10.1016\/j.annonc.2024.05.537.","journal-title":"Ann Oncol"},{"key":"7748_CR15","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s00259-023-06461-4","volume":"51","author":"C Civan","year":"2024","unstructured":"Civan C, Kuyumcu S, Has Simsek D, Sanli O, Isik EG, Ozkan ZG, et al. The role of [(68) Ga]Ga-FAPI-04 PET\/CT in renal cell carcinoma: a preliminary study. Eur J Nucl Med Mol Imaging. 2024;51:852\u201361. https:\/\/doi.org\/10.1007\/s00259-023-06461-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7748_CR16","doi-asserted-by":"publisher","first-page":"888","DOI":"10.2967\/jnumed.123.267260","volume":"65","author":"MJ Hagens","year":"2024","unstructured":"Hagens MJ, van Leeuwen PJ, Wondergem M, Boellaard TN, Sanguedolce F, Oprea-Lager DE, et al. A systematic review on the diagnostic value of fibroblast activation protein inhibitor PET\/CT in genitourinary cancers. J Nucl Med. 2024;65:888\u201396. https:\/\/doi.org\/10.2967\/jnumed.123.267260.","journal-title":"J Nucl Med"},{"key":"7748_CR17","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00259-022-06101-3","volume":"50","author":"G Wang","year":"2023","unstructured":"Wang G, Li L, Wang J, Zang J, Chen J, Xiao Y, et al. Head-to-head comparison of [(68)Ga]Ga-P16-093 and 2-[(18)F]FDG PET\/CT in patients with clear cell renal cell carcinoma: a pilot study. Eur J Nucl Med Mol Imaging. 2023;50:1499\u2013509. https:\/\/doi.org\/10.1007\/s00259-022-06101-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7748_CR18","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1007\/s00259-024-06672-3","volume":"51","author":"Q Wu","year":"2024","unstructured":"Wu Q, Wu Y, Zhang Y, Guan Y, Huang G, Xie F, et al. ImmunoPET\/CT imaging of clear cell renal cell carcinoma with [(18)F]RCCB6: a first-in-human study. Eur J Nucl Med Mol Imaging. 2024;51:2444. https:\/\/doi.org\/10.1007\/s00259-024-06672-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7748_CR19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.eururo.2024.06.020","volume":"86","author":"Q Wu","year":"2024","unstructured":"Wu Q, Wu Y, Zhang Y, Guan Y, Huang G, Zheng J, et al. [(18)F]RCCB6 immuno-positron emission tomography\/computed tomography for postoperative surveillance in clear cell renal cell carcinoma: a pilot clinical study. Eur Urol. 2024;86(4):372. https:\/\/doi.org\/10.1016\/j.eururo.2024.06.020.","journal-title":"Eur Urol"},{"key":"7748_CR20","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.eururo.2022.01.040","volume":"81","author":"E Roussel","year":"2022","unstructured":"Roussel E, Capitanio U, Kutikov A, Oosterwijk E, Pedrosa I, Rowe SP, et al. Novel imaging methods for renal mass characterization: a collaborative review. Eur Urol. 2022;81:476. https:\/\/doi.org\/10.1016\/j.eururo.2022.01.040.","journal-title":"Eur Urol"},{"key":"7748_CR21","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","volume":"25","author":"B Shuch","year":"2024","unstructured":"Shuch B, Pantuck AJ, Bernhard JC, Morris MA, Master V, Scott AM, et al. [(89)Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024;25:1277. https:\/\/doi.org\/10.1016\/S1470-2045(24)00402-9.","journal-title":"Lancet Oncol"},{"issue":"9","key":"7748_CR22","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s00259-019-04358-9","volume":"46","author":"SR Verhoeff","year":"2019","unstructured":"Verhoeff SR, van Es SC, Boon E, van Helden E, Angus L, Elias SG, et al. Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET\/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019;46(9):1931. https:\/\/doi.org\/10.1007\/s00259-019-04358-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7748_CR23","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1007\/s00259-024-06801-y","volume":"51","author":"W Zhu","year":"2024","unstructured":"Zhu W, Zheng G, Yan X, Liu M, Li X, Cheng Y, et al. Diagnostic efficacy of [(68)Ga]Ga-NY104 PET\/CT to identify clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2024;51:4127. https:\/\/doi.org\/10.1007\/s00259-024-06801-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7748_CR24","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.2967\/jnumed.124.267527","volume":"65","author":"K Lou","year":"2024","unstructured":"Lou K, Wang J, He H, Wang Y, Mi Y, Li W, et al. Value of [(68)Ga]Ga-NYM046 PET\/CT, in comparison with (18)F-FDG PET\/CT, for diagnosis of clear cell renal cell carcinoma. J Nucl Med. 2024;65:1884\u201390. https:\/\/doi.org\/10.2967\/jnumed.124.267527.","journal-title":"J Nucl Med"},{"key":"7748_CR25","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s00259-024-07007-y","volume":"52","author":"L Yang","year":"2025","unstructured":"Yang L, Guo W, Ding H, Gao X, Xu Y, Wang M, et al. Evaluation of the safety, biodistribution, dosimetry of [(18)F]AlF-NYM005 and initial experience in clear cell renal cell carcinoma: an interim analysis of a prospective trial. Eur J Nucl Med Mol Imaging. 2025;52:1354. https:\/\/doi.org\/10.1007\/s00259-024-07007-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7748_CR26","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet"},{"issue":"2","key":"7748_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00259-023-06436-5","volume":"51","author":"R Lin","year":"2024","unstructured":"Lin R, Wang C, Chen S, Lin T, Cai H, Chen S. <article-title update=\"added\">[68Ga]Ga\u2011LNC1007 PET\/CT in the evaluation of renal cell carcinoma: comparison with 2-[18F]FDG\/[68Ga]Ga-PSMA PET\/CT. Eur J Nucl Med Mol Imaging. 2024;51(2):535\u201347. https:\/\/doi.org\/10.1007\/s00259-023-06436-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7748_CR28","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1007\/s00259-017-3779-0","volume":"44","author":"J Huang","year":"2017","unstructured":"Huang J, Huang L, Zhou J, Duan Y, Zhang Z, Wang X, et al. <article-title update=\"added\">Elevated tumor-to-liver uptake ratio (TLR) from 18F\u2013FDG-PET\/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection. Eur J Nucl Med Mol Imaging. 2017;44:1958\u201368. https:\/\/doi.org\/10.1007\/s00259-017-3779-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7748_CR29","doi-asserted-by":"publisher","first-page":"849","DOI":"10.2214\/AJR.16.17133","volume":"208","author":"C Nicolau","year":"2017","unstructured":"Nicolau C, Sala E, Kumar A, Goldman DA, Schoder H, Hricak H, et al. Renal masses detected on FDG PET\/CT in patients with lymphoma: imaging features differentiating primary renal cell carcinomas from renal lymphomatous involvement. AJR Am J Roentgenol. 2017;208:849\u201353. https:\/\/doi.org\/10.2214\/AJR.16.17133.","journal-title":"AJR Am J Roentgenol"},{"key":"7748_CR30","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/sj.bjc.6605690","volume":"102","author":"M Ilie","year":"2010","unstructured":"Ilie M, Mazure NM, Hofman V, Ammadi RE, Ortholan C, Bonnetaud C, et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer. 2010;102:1627\u201335. https:\/\/doi.org\/10.1038\/sj.bjc.6605690.","journal-title":"Br J Cancer"},{"key":"7748_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159\u201374.","journal-title":"Biometrics"},{"key":"7748_CR32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.urolonc.2009.03.028","volume":"29","author":"N Lawrentschuk","year":"2011","unstructured":"Lawrentschuk N, Lee FT, Jones G, Rigopoulos A, Mountain A, O\u2019Keefe G, et al. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (1)(2)(4)I-cG250 PET\/CT. Urol Oncol. 2011;29:411\u201320. https:\/\/doi.org\/10.1016\/j.urolonc.2009.03.028.","journal-title":"Urol Oncol"},{"key":"7748_CR33","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1007\/s00259-021-05271-w","volume":"48","author":"RIJ Merkx","year":"2021","unstructured":"Merkx RIJ, Lobeek D, Konijnenberg M, Jimenez-Franco LD, Kluge A, Oosterwijk E, et al. <article-title update=\"added\">Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:3277\u201385. https:\/\/doi.org\/10.1007\/s00259-021-05271-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7748_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.2011.41.2445","volume":"31","author":"CR Divgi","year":"2013","unstructured":"Divgi CR, Uzzo RG, Gatsonis C, Bartz R, Treutner S, Yu JQ, et al. Positron emission tomography\/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol. 2013;31:187\u201394. https:\/\/doi.org\/10.1200\/JCO.2011.41.2445.","journal-title":"J Clin Oncol"},{"key":"7748_CR35","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.medj.2024.10.003","volume":"5","author":"C Hage Chehade","year":"2024","unstructured":"Hage Chehade C, Gebrael G, Agarwal N. [(89)Zr]Zr-girentuximab PET-CT imaging to diagnose, characterize, and differentiate clear-cell renal cell carcinoma. Med. 2024;5:1345\u20137. https:\/\/doi.org\/10.1016\/j.medj.2024.10.003.","journal-title":"Med"},{"key":"7748_CR36","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1007\/s00259-023-06248-7","volume":"50","author":"W Zhu","year":"2023","unstructured":"Zhu W, Li X, Zheng G, Bai C, Ji Z, Zhang H, et al. Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2023;50:3116\u201325. https:\/\/doi.org\/10.1007\/s00259-023-06248-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7748_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1053\/snuc.2002.29270","volume":"32","author":"JS Fowler","year":"2002","unstructured":"Fowler JS, Ido T. Initial and subsequent approach for the synthesis of 18FDG. Semin Nucl Med. 2002;32:6\u201312. https:\/\/doi.org\/10.1053\/snuc.2002.29270.","journal-title":"Semin Nucl Med"},{"key":"7748_CR38","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/RLU.0000000000000875","volume":"40","author":"M Takahashi","year":"2015","unstructured":"Takahashi M, Kume H, Koyama K, Nakagawa T, Fujimura T, Morikawa T, et al. Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET\/CT. Clin Nucl Med. 2015;40:936\u201340. https:\/\/doi.org\/10.1097\/RLU.0000000000000875.","journal-title":"Clin Nucl Med"},{"key":"7748_CR39","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0022-5347(05)65845-4","volume":"166","author":"S Ramdave","year":"2001","unstructured":"Ramdave S, Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HT, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol. 2001;166:825\u201330.","journal-title":"J Urol"},{"key":"7748_CR40","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1158\/1078-0432.CCR-22-0921","volume":"29","author":"SR Verhoeff","year":"2023","unstructured":"Verhoeff SR, Oosting SF, Elias SG, van Es SC, Gerritse SL, Angus L. [89Zr]Zr-DFO-girentuximab and [18F]FDG PET\/CT to predict watchful waiting duration in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 2023;29:592\u2013601. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0921.","journal-title":"Clin Cancer Res"},{"key":"7748_CR41","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","volume":"87","author":"A Bex","year":"2025","unstructured":"Bex A, Ghanem YA, Albiges L, Bonn S, Campi R, Capitanio U, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: the 2025 update. Eur Urol. 2025;87:683\u201396. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.020.","journal-title":"Eur Urol"},{"key":"7748_CR42","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1113205.","journal-title":"N Engl J Med"},{"key":"7748_CR43","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/his.14204","volume":"77","author":"N Baniak","year":"2020","unstructured":"Baniak N, Flood TA, Buchanan M, Dal Cin P, Hirsch MS. Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes. Histopathology. 2020;77:659\u201366. https:\/\/doi.org\/10.1111\/his.14204.","journal-title":"Histopathology"},{"key":"7748_CR44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/PAS.0b013e3181570343","volume":"32","author":"HA Al-Ahmadie","year":"2008","unstructured":"Al-Ahmadie HA, Alden D, Qin LX, Olgac S, Fine SW, Gopalan A, et al. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Am J Surg Pathol. 2008;32:377\u201382. https:\/\/doi.org\/10.1097\/PAS.0b013e3181570343.","journal-title":"Am J Surg Pathol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07748-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07748-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07748-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:26:23Z","timestamp":1777274783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07748-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7748"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07748-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article was modified to correct the placement of Table 2 and Table 3. An article note was also added.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were carried out in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any experiments with animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}